Syndax Pharmaceuticals is under investigation by Pomerantz LLP for possible securities fraud following the failure of its MAXPIRe Phase 2 trial for axatilimab in idiopathic pulmonary fibrosis, which missed its primary endpoint. The trial news caused Syndax's stock to drop 2.59% on October 12, 2026. The investigation will determine if Syndax and its officers engaged in unlawful business practices. Investors affected are advised to contact the law firm for potential class action participation.
Syndax Pharmaceuticals investigation news provides context for health sector performance on Pluang. For readers following health stocks, here is Pluang's market snapshot as of Nov 06, 2026 05:11 WIB: out of 150 priced health-sector US stocks, 17 rose and 133 fell. Notable movers include NUWE at USD 4.60 with a -12.71% change and 100% buy orders, NUVB at USD 4.16 with a -12.05% change and a near-even buy/sell split, and HIMS at USD 23.56 with a -11.63% change and 65% buy orders. Typical hold times range from 11 to 31 days.
Ademi LLP is investigating Strategic Education for potential securities fraud related to inaccurate statements about its financials and business operations, particularly in Australia. This probe follows a more than 20% decline in the company's stock ...
Corporate Insight released research identifying top financial firms leading in customer-facing AI tools, including virtual assistants and AI-powered fintech platforms. Fidelity and Voya lead in retirement plan virtual assistants, while Lively excels ...
Strawberry Fields REIT announced a cash dividend of $0.17 per common share for the fourth quarter of 2026. The dividend will be paid on December 30, 2026, to shareholders recorded by December 16, 2026. The company specializes in owning and leasing he...
Evolus, Inc. is under investigation by Pomerantz LLP following an FDA warning about a misleading Instagram promotion for its wrinkle treatment Jeuveau. The FDA criticized the ad for downplaying safety risks and making exaggerated claims about the pro...
Erasca, Inc. announced the termination of its Chief Operating Officer, Nicholas Chetwyn, effective November 2, 2026, as part of a leadership realignment to support its RAS-targeting programs. Following this announcement, Erasca's stock price fell nea...
